Opthea is developing a treatment for wet AMD, OPT-302, to be used as a combination therapy with existing treatments. OPT-302 targets proteins that cause blood vessels in the retina to grow and leak, leading to vision problems. Wet AMD is an age-related form of macular degeneration and although there is some hereditary component, the exact cause is unknown. There is a strong correlation with age – wet AMD is a leading cause of blindness in over 55s.
Phylogica is seeking to develop gene-disrupting therapies for inherited retinal diseases using a proprietary cell-penetrating peptide bound to an antisense oligonucleotide. It has yet to reveal which specific disease/diseases it is targeting. However, the information available and testing to date suggests to me that the company will likely target retinal dystrophies that have a specific, identifiable gene mutation, and likely something that qualifies as an orphan drug.
Therefore, I believe it is highly unlikely that there will be competition with Opthea’s pipeline, which is targeting wet AMD and Diabetic Macular Oedema.
Just my thoughts.
PYC Price at posting:
3.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)